USPTO Files ISSUE NOTIFICATION for BetterLife's BETR-001 Composition of Matter Patent

(TheNewswire)

VANCOUVER, British Columbia, June 18, 2025 – TheNewswire - BetterLifePharma Inc. (“BetterLife” or the “Compa ny”) ( CSE:BETR / OTCQB :BETRF / FRA: NPAU ) ,an emerging biotech company focused on the development of BETR-001, anon-hallucinogenic neuroplastogen in the treatment of psychiatric andneurological disorders, is pleased to announce that the United StatesPatent and Trademark Office (US PTO) has filed ISSUE NOTIFICATION for BETR-001 composition of matter patent US 12331051 (ApplicationPub. No. US 2023/0357253 A1) on June 17, 2025.

Click Image To View Full Size

FIGURE: June 17, 2025 IssueNotification.

Full issuance can be viewed here .

The Issue Notification for this patent covers a numberof claims to crystalline forms of the compound, formulationsrelated to the crystalline compound, and  isomers.

Dr. Ahmad Doroudian, CEO of BetterLife commented, “Weare extremely pleased with the grant of this composition of matterpatent which covers BETR-001 as well as its related derivates.Composition of matter patent is the strongest level of intellectualproperty coverage one can get for a compound. This patent givesBETR-001 robust intellectual property coverage until at least2042.”

He further added, “Based on its excellentneuroplasticity data, its neuroreceptor activation profile andpreliminary data obtained in animal models, BETR-001 is projected tobe effective in treating various psychiatric and neurologicaldisorders including depression, anxiety, PTSD, traumatic brain injury,migraines and neuropathic pain.”

BETR-001 is non-hallucinogenic and not a controlledsubstance. BetterLife has had its BETR-001pre-IND meeting with the FDA and has completed most of the requiredIND-enabling studies. The BETR-001 IND filing and start of humantrials are projected for H1 2026.

The Company also announces that it has issued a totalof 6,473,712 common shares and 6,473,712 share purchase warrantspursuant to the conversion option of convertible debentures andaccrued interest on convertible debentures totaling $647,371.  Sharepurchase warrants are exercisable into common shares, on a one-for-onebasis, at an exercise price of $0.10 per warrant and expire onDecember 31, 2025, September 27, 2026 and October 1, 2026.

About BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnologycompany primarily focused on developing and commercializing twocompounds, BETR-001 and BETR-002, to treat neuro-psychiatric andneurological disorders.

BETR-001, which is in preclinical and IND-enablingstudies, is a non-hallucinogenic neuroplastogen. BETR-001 is anon-controlled substance. BETR-001 will be developed for the treatmentof various psychiatric and neurological disorders. BETR-001 pendingpatent, for composition and method of use, covers treatment of majordepressive disorder, anxiety disorder and neuropathic pain and otherneuro-psychiatric and neurological disorders.

BETR-002, which is in preclinical and IND-enablingstudies, is based on honokiol, the active anxiolytic ingredient ofmagnolia bark. BetterLife’s pending method of use and formulationspatent covers treatment of anxiety-related disorders includingbenzodiazepine dependency.

BetterLife also owns a drug candidate for the treatmentof viral infections and is in the process of seeking strategicalternatives for further development.

For further information, please visit BetterLifePharma .

Contact

David Melles, Investor Relations Manager

Email: David.Melles@blifepharma.com

Phone: 1-778-887-1928

Cautionary Note RegardingForward-Looking Statements

No securities exchange has reviewed nor acceptsresponsibility for the adequacy or accuracy of the content of thisnews release. This news release contains forward-looking statementsrelating to product development, licensing,commercialization and regulatory compliance issues and otherstatements that are not historical facts. Forward-looking statementsare often identified by terms such as “will”, “may”,“should”, “anticipate”, “expects” and similar expressions.All statements other than statements of historical fact, included inthis release are forward-looking statements that involve risks anduncertainties. There can be no assurance that such statements willprove to be accurate and actual results and future events could differmaterially from those anticipated in such statements. Importantfactors that could cause actual results to differ materially from theCompany’s expectations include the failure to satisfy the conditionsof the relevant securities exchange(s) and other risks detailed fromtime to time in the filings made by the Company with securitiesregulations. The reader is cautioned that assumptions used in thepreparation of any forward-looking information may prove to beincorrect. Events or circumstances may cause actual results to differmaterially from those predicted, as a result of numerous known andunknown risks, uncertainties, and other factors, many of which arebeyond the control of the Company. The reader is cautioned not toplace undue reliance on any forward-looking information. Suchinformation, although considered reasonable by management at the timeof preparation, may prove to be incorrect and actual results maydiffer materially from those anticipated. Forward-looking statementscontained in this news release are expressly qualified by thiscautionary statement. The forward-looking statements contained in thisnews release are made as of the date of this news release and theCompany will update or revise publicly any of the includedforward-looking statements as expressly required by applicablelaw.

Copyright (c) 2025 TheNewswire - All rights reserved.